IP Library › Granted Patent US 7,964,646
Granted Patent B2
US 7,964,646 · App. 11/500,739 · Granted Jun 21, 2011

3,4-DI-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,964,646
App. No.
11/500,739
Granted
Jun 21, 2011
Kind
B2
Abstract

There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.

Claims (47)

1. A compound selected from the group consisting of

2. The compound of claim 1 wherein said compound is a calcium or sodium salt.

3. A pharmaceutical composition comprising an effective amount of a compound of claim 1 in combination with a pharmaceutically acceptable carrier.

4. The compound of claim 1 wherein said compound is:

5. The compound of claim 1 wherein said compound is:

6. The compound of claim 1 wherein said compound is:

7. The compound of claim 1 wherein said compound is:

8. The compound of claim 1 wherein said compound is:

9. The compound of claim 1 wherein said compound is:

10. The compound of claim 1 wherein said compound is:

11. The compound of claim 1 wherein said compound is:

12. The compound of claim 1 wherein said compound is:

13. The compound of claim 1 wherein said compound is:

14. The compound of claim 1 wherein said compound is:

15. The compound of claim 1 wherein said compound is:

16. The compound of claim 1 wherein said compound is:

17. The compound of claim 1 wherein said compound is:

18. The compound of claim 1 wherein said compound is:

19. The compound of claim 1 wherein said compound is:

20. The compound of claim 1 wherein said compound is:

21. The compound of claim 1 wherein said compound is:

22. The compound of claim 1 wherein said compound is:

23. The compound of claim 1 wherein said compound is:

24. The compound of claim 1 wherein said compound is:

25. The compound of claim 1 wherein said compound is:

26. The compound of claim 1 wherein said compound is:

27. The compound of claim 1 wherein said compound is:

28. The compound of claim 1 wherein said compound is:

29. A compound selected from the group consisting of

30. The compound of claim 29 wherein said compound is:

31. The compound of claim 29 wherein said compound is:

32. The compound of claim 29 wherein said compound is:

33. The compound of claim 29 wherein said compound is:

34. The compound of claim 29 wherein said compound is:

35. The compound of claim 29 wherein said compound is:

36. The compound of claim 29 wherein said compound is:

37. The compound of claim 29 wherein said compound is:

38. The compound of claim 29 wherein said compound is:

39. The compound of claim 29 wherein said compound is:

40. A compound selected from the group consisting of

41. The compound of claim 40 wherein said compound is:

42. The compound of claim 40 wherein said compound is:

43. The compound of claim 40 wherein said compound is:

44. The compound of claim 29 wherein said compound is a calcium or sodium salt.

45. A pharmaceutical composition comprising an effective amount of a compound of claim 29 in combination with a pharmaceutically acceptable carrier.

46. The compound of claim 40 wherein said compound is a calcium or sodium salt.

47. A pharmaceutical composition comprising an effective amount of a compound of claim 40 in combination with a pharmaceutically acceptable carrier.

Assignments (1)
CHANGE OF NAME Recorded Aug 30, 2012
From: SCHERING CORPORATION
To: MERCK SHARP & DOHME CORP.
Reel/Frame 028884/0151 →